This firm's average rating is Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Acer Therapeutics market sentiment investors' perception of the future value of Acer Therapeutics. Let us look at a few aspects of Acer Therapeutics technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Acer Therapeutics. In general, sophisticated investors focus on analyzing Acer Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Acer Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Acer Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Acer Therapeutics, many experienced traders also check how macroeconomic factors affect Acer Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Acer Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acer Therapeutics. Your research has to be compared to or analyzed against Acer Therapeutics' peers to derive any actionable benefits. When done correctly, Acer Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Acer Therapeutics.
Watch out for price decline
Please consider monitoring Acer Therapeutics on a daily basis if you are holding a position in it. Acer Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Acer Therapeutics stock to be traded above the $1 level to remain listed. If Acer Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Acer Stands against Peers?
Analyzing Acer Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Acer Therapeutics across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Acer Therapeutics Competition DetailsCloser look at Acer Therapeutics Mean Deviation
Acer Therapeutics has current Mean Deviation of 2.59. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.
Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.
Mean Deviation | = | SUM(RET DEV) N |
| = | 2.59 |
| SUM | = | Summation notation |
| RET DEV | = | Sum of return deviations of Acer Therapeutics |
| N | = | Number of calculation points for selected time horizon |
Let's now compare Acer Therapeutics Mean Deviation to its closest peers:
| ACER | 2.5949266712580354 |
| EARS | 12.51 |
| DTIL | 4.45 |
| EQ | 5.38 |
| DYAI | 2.25 |
Will Acer Therapeutics latest spike continue?
The semi deviation is down to 2.77 as of today. Acer Therapeutics currently demonstrates below-verage downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.05. However, we do advice investors to further question Acer Therapeutics expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.
Our Conclusion on Acer Therapeutics
While many other companies under the biotechnology industry are still a bit expensive, Acer Therapeutics may offer a potential longer-term growth to retail investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Acer Therapeutics as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Acer Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Acer Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com